<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01908582</url>
  </required_header>
  <id_info>
    <org_study_id>14636</org_study_id>
    <secondary_id>I1V-MC-EIAZ</secondary_id>
    <nct_id>NCT01908582</nct_id>
  </id_info>
  <brief_title>A Study of Evacetrapib and Rifampin in Healthy Participants</brief_title>
  <official_title>Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine how much evacetrapib gets into the blood
      stream and how long it takes the body to get rid of it when given with rifampin. The safety
      and tolerability of the two drugs, given together, will also be evaluated. The study will
      also look at blood cholesterol levels and levels of a hormone called cortisol before and
      after taking rifampin. Information about any side effects that may occur will also be
      collected.

      For each participant, this study will include 2 periods in fixed order. The study will last
      approximately 29 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Maximum concentration (Cmax) of Evacetrapib</measure>
    <time_frame>Day 1 and Day 16, predose of evacetrapib through 168 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (tmax) of Evacetrapib</measure>
    <time_frame>Day 1 and Day 16, predose of evacetrapib through 168 hours post dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics, Area Under the Plasma Concentration-Time Curve From Time 0 Hour (h) to Infinity (AUC0-âˆž) of Evacetrapib</measure>
    <time_frame>Day 1 and Day 16, predose of evacetrapib through 168 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Evacetrapib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>130 milligram (mg) evacetrapib administered orally, once on Day 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib + Rifampin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rifampin: 600 mg administered orally, once daily (QD) for 14 days (Days 9-22)
Evacetrapib: 130 mg administered orally once on Day 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evacetrapib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Evacetrapib</arm_group_label>
    <arm_group_label>Evacetrapib + Rifampin</arm_group_label>
    <other_name>LY2484595</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Evacetrapib + Rifampin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly healthy males and females (of non child-bearing potential)

          -  Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2), inclusive, at
             screening

        Exclusion Criteria:

          -  Have known allergies to evacetrapib, rifampin, related compounds or any components of
             either formulation, or history of significant allergic disease as determined by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2013</study_first_submitted>
  <study_first_submitted_qc>July 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2013</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Evacetrapib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 18, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

